7月16日,CDE官网显示,百济神州与安进合作开发的注射用塔拉妥单抗上市申请正式获受理。该药物此前已被纳入优先审评程序,拟用于既往接受过至少二线治疗(包括含铂化疗)失败的广泛期小细胞肺癌成人患者。塔拉妥单抗是一款同类首创的DLL3/CD3双特异性抗体,属于创新的T细胞衔接器免疫疗法。作为全球首个获批用于实体瘤的BiTE药物,此次在中国的上市申请标志着我国小细胞肺癌治疗领域或将迎来革命性突破。肺癌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.